Introduction – Addressing Core Uncontrolled Severe Asthma, Eosinophilic Inflammation, and Corticosteroid Dependence
For pulmonologists, allergists, and respiratory care specialists, severe eosinophilic asthma (SEA) – a subtype of severe asthma characterized by elevated blood and sputum eosinophil levels (≥300 cells/μL) – is associated with frequent exacerbations, poor lung function (low FEV1), reduced quality of life, and high healthcare utilization. Standard high-dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) may inadequately control inflammation, leaving patients corticosteroid-dependent and at risk for systemic steroid side effects (osteoporosis, weight gain, diabetes, immune suppression). Severe eosinophilic asthma treatments – therapeutic regimens including biologics (monoclonal antibodies) targeting eosinophil-driven inflammation (interleukin-5 (IL-5), IL-5 receptor (IL-5Rα), and IL-4/IL-13 pathways) – directly address this unmet medical need by reducing exacerbations (up to 50-70%), improving lung function (FEV1 increases), and lowering or eliminating oral corticosteroid (OCS) use. Key biologics include: mepolizumab (Nucala, GSK) – anti-IL-5; reslizumab (Cinqair, Teva) – anti-IL-5; benralizumab (Fasenra, AstraZeneca) – anti-IL-5Rα (induces eosinophil apoptosis); dupilumab (Dupixent, Sanofi/Regeneron) – anti-IL-4/IL-13. These therapies are administered via subcutaneous injection (benralizumab, mepolizumab, dupilumab) or intravenous infusion (reslizumab). The market for severe eosinophilic asthma treatments is expanding due to rising prevalence of respiratory diseases, increased diagnosis rates (blood eosinophil testing), improved access to specialty drugs, and favorable reimbursement policies. As biologics become standard-of-care for uncontrolled severe asthma, companies focus on innovative targeted therapies and long-term safety to strengthen clinical competitiveness. This deep-dive analysis integrates QYResearch’s latest forecasts (2026–2032), administration route segmentation, and patient population insights.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Severe Eosinophilic Asthma Treatment – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Severe Eosinophilic Asthma Treatment market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Severe Eosinophilic Asthma Treatment was estimated to be worth US8420millionin2025andisprojectedtoreachUS8420millionin2025andisprojectedtoreachUS 17262 million, growing at a CAGR of 10.8% from 2026 to 2032. The gross profit margin of major companies in the industry is between 58% – 78%. Severe Eosinophilic Asthma Treatment refers to therapeutic regimens used for patients with severe asthma characterized by elevated eosinophil-driven inflammation. The category includes biologics, targeted monoclonal antibodies, and advanced maintenance therapies aimed at reducing exacerbations, improving lung function, and lowering corticosteroid dependence. It has become an important segment within specialty respiratory care and precision immunology treatment. The industrial chain of Severe Eosinophilic Asthma Treatment includes upstream biologic raw materials, cell culture media, active pharmaceutical ingredients, vials, syringes, and cold-chain materials. Midstream covers drug development, biomanufacturing, filling, packaging, and regulatory control. Downstream applications mainly include hospitals, specialty clinics, respiratory care centers, pharmacies, and long-term chronic disease management programs.
The market for severe eosinophilic asthma treatments is expanding due to rising prevalence of respiratory diseases and unmet medical needs. Biologics targeting eosinophilic inflammation have become mainstream for uncontrolled severe asthma. Increasing diagnosis rates, improved access to specialty drugs, and favorable reimbursement policies support growth. Companies focus on innovative targeted therapies and long-term safety to strengthen clinical competitiveness.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5733303/severe-eosinophilic-asthma-treatment
Core Keywords (Embedded Throughout)
- Severe eosinophilic asthma treatment
- Eosinophilic inflammation
- Biologics for asthma
- Anti-IL-5
- Monoclonal antibody
Market Segmentation by Administration Route and Patient Population
The severe eosinophilic asthma treatment market is segmented below by both dosing regimen (type) and age group (application). Understanding this matrix is essential for pharmaceutical companies targeting specific patient preferences and clinical settings.
By Type (Administration Route / Healthcare Setting):
- Intravenous Infusion (administered in clinic/hospital setting by healthcare professional (IV infusion). Typically every 4 weeks. Reslizumab (Cinqair) requires IV infusion. Higher healthcare resource utilization, but may be preferred for patients unable to self-inject)
- Subcutaneous Injection (administered by patient at home (self-injection) via pre-filled syringe or auto-injector. Dosing: mepolizumab (100 mg every 4 weeks), benralizumab (30 mg every 8 weeks after initial loading), dupilumab (200-300 mg every 2 weeks). Convenient, lower healthcare costs, preferred by patients)
By Application (Patient Demographics / Age Group):
- Adult Severe Eosinophilic Asthma (≥18 years, majority of patients)
- Adolescent Severe Eosinophilic Asthma (12-17 years)
- Elderly Comorbid Asthma (≥65 years, often with comorbidities (COPD, cardiovascular disease, diabetes), may have altered response, safety considerations)
Industry Stratification: Key Biologics for Severe Eosinophilic Asthma
Mepolizumab (Nucala, GSK): anti-IL-5 monoclonal antibody. Reduces blood eosinophils, exacerbations (by ~50%), OCS use. SC injection (100mg). Approved for adults and adolescents (6+ years).
Reslizumab (Cinqair, Teva): anti-IL-5 monoclonal antibody. IV infusion (3 mg/kg) every 4 weeks. Approved for adults.
Benralizumab (Fasenra, AstraZeneca): anti-IL-5Rα monoclonal antibody. Induces antibody-dependent cell-mediated cytotoxicity (ADCC) of eosinophils, faster depletion. SC injection (30mg). Dosing: every 4 weeks × 3 doses, then every 8 weeks. Approved for adults and adolescents (12+ years).
Dupilumab (Dupixent, Sanofi/Regeneron): anti-IL-4Rα (blocks IL-4 and IL-13 signaling). Reduces type 2 inflammation (eosinophils, FeNO). Approved for severe asthma (≥6 years), also for atopic dermatitis, nasal polyps. SC injection.
Recent 6-Month Industry Data (September 2025 – February 2026)
- Severe Eosinophilic Asthma Market: 8.42Bin2025,projected8.42Bin2025,projected17.26B by 2032, 10.8% CAGR.
- Biologic Penetration (November 2025): 20-25% of severe asthma patients receive biologics (increasing).
- Real-World Evidence (December 2025): Benralizumab reduces OCS use by 75% in severe eosinophilic asthma.
- Innovation data (Q4 2025): AstraZeneca “Fasenra SC (Benralizumab) 3mL pre-filled syringe” – 30mg, 8-week dosing, for adult and adolescent (12+) severe eosinophilic asthma.
Typical User Case – Severe Uncontrolled Asthma (Adult)
A 45-year-old patient with severe eosinophilic asthma (blood eosinophils 600 cells/μL, FEV1 55% predicted, 3 exacerbations/year requiring OCS) initiates benralizumab (subcutaneous injection, 30mg every 8 weeks).
After 6 months: exacerbations reduced to 0, FEV1 improved to 70%, OCS discontinued.
Mechanism: eosinophils depleted (<10 cells/μL), airway inflammation reduced.
Technical Difficulties and Current Solutions
Despite clinical success, severe eosinophilic asthma treatment faces four persistent challenges:
- High cost of biologics ($30,000-40,000/year). Biosimilars pending (mepolizumab, dupilumab).
- Patient selection (biomarkers). blood eosinophil count ≥300 cells/μL predicts response.
- Non-response (15-20%). Switch to alternative biologic (anti-IL-5 vs anti-IL-4/13).
- Adherence (patient-administered injections). Auto-injector, patient education.
Exclusive Industry Observation – The Severe Eosinophilic Asthma Market by Route and Region
Based on QYResearch’s interviews with 71 allergy/asthma specialists (October 2025 – January 2026), subcutaneous injection dominant (patient convenience); IV infusion declining (reslizumab).
SC – 85% of biologics.
IV – 15%.
For suppliers, key strategy: focus on subcutaneous biologics (self-injection, less frequent dosing (8 weeks vs 4 weeks)); develop biosimilars to reduce cost, improve access.
Complete Market Segmentation (as per original data)
The Severe Eosinophilic Asthma Treatment market is segmented as below:
Major Players:
AstraZeneca, GSK (GlaxoSmithKline), Sanofi, Regeneron Pharmaceuticals, Novartis, Roche (Genentech), Teva Pharmaceutical, Amgen, TEPPON (Kyowa Kirin), Jiangsu Hengrui Pharmaceuticals, CSPC Pharmaceutical Group, 3SBio (Sunshine Guojian), Akeso, InnoCare Pharma, Innovent Biologics, Mabwell Bioscience
Segment by Type:
Intravenous Infusion, Subcutaneous Injection
Segment by Application:
Adult Severe Eosinophilic Asthma, Adolescent Severe Eosinophilic Asthma, Elderly Comorbid Asthma
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
